MX2013005699A - Composiciones de interferon-beta estables conservadas. - Google Patents
Composiciones de interferon-beta estables conservadas.Info
- Publication number
- MX2013005699A MX2013005699A MX2013005699A MX2013005699A MX2013005699A MX 2013005699 A MX2013005699 A MX 2013005699A MX 2013005699 A MX2013005699 A MX 2013005699A MX 2013005699 A MX2013005699 A MX 2013005699A MX 2013005699 A MX2013005699 A MX 2013005699A
- Authority
- MX
- Mexico
- Prior art keywords
- interferon
- beta
- preserved compositions
- stable preserved
- stable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000003996 Interferon-beta Human genes 0.000 title 1
- 108090000467 Interferon-beta Proteins 0.000 title 1
- 229960001388 interferon-beta Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41629110P | 2010-11-22 | 2010-11-22 | |
| PCT/US2011/061759 WO2012071366A1 (en) | 2010-11-22 | 2011-11-22 | Stable preserved compositions if interferon-beta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013005699A true MX2013005699A (es) | 2013-08-27 |
Family
ID=46146183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013005699A MX2013005699A (es) | 2010-11-22 | 2011-11-22 | Composiciones de interferon-beta estables conservadas. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120269770A1 (enExample) |
| EP (1) | EP2643469A1 (enExample) |
| JP (1) | JP2013543872A (enExample) |
| AU (1) | AU2011331992A1 (enExample) |
| CA (1) | CA2818671A1 (enExample) |
| MX (1) | MX2013005699A (enExample) |
| WO (1) | WO2012071366A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014130811A1 (en) * | 2013-02-22 | 2014-08-28 | Biogen Idec Ma Inc | Interferon beta formulation |
| WO2016163764A2 (ko) * | 2015-04-07 | 2016-10-13 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
| FI126979B (en) * | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and its use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1272252B (it) * | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| BRPI0510526A (pt) * | 2004-06-01 | 2007-10-30 | Ares Trading Sa | formulações lìquidas estabilizadas de interferon |
| CN101878043A (zh) * | 2007-12-20 | 2010-11-03 | 默克雪兰诺有限公司 | PEG-干扰素-β制剂 |
-
2011
- 2011-11-21 US US13/301,354 patent/US20120269770A1/en not_active Abandoned
- 2011-11-22 AU AU2011331992A patent/AU2011331992A1/en not_active Abandoned
- 2011-11-22 WO PCT/US2011/061759 patent/WO2012071366A1/en not_active Ceased
- 2011-11-22 MX MX2013005699A patent/MX2013005699A/es not_active Application Discontinuation
- 2011-11-22 CA CA2818671A patent/CA2818671A1/en not_active Abandoned
- 2011-11-22 EP EP11843556.9A patent/EP2643469A1/en not_active Withdrawn
- 2011-11-22 JP JP2013540105A patent/JP2013543872A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013543872A (ja) | 2013-12-09 |
| WO2012071366A8 (en) | 2013-06-20 |
| WO2012071366A1 (en) | 2012-05-31 |
| US20120269770A1 (en) | 2012-10-25 |
| AU2011331992A1 (en) | 2013-06-13 |
| EP2643469A1 (en) | 2013-10-02 |
| CA2818671A1 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN00548A (enExample) | ||
| IN2012DN00746A (enExample) | ||
| PH12012501355A1 (en) | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | |
| AU333422S (en) | Showerhead | |
| PH12013500870A1 (en) | Heterocyclic compounds and uses thereof | |
| PH12013500386A1 (en) | Pesticidal compositions | |
| MX2015013686A (es) | Composiciones y metodos para potenciar la estabilidad microbiana. | |
| MY162837A (en) | Modified relaxin polypeptides and their uses | |
| MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
| MX2013004981A (es) | Composiciones y metodos para la administracion de agentes terapeuticos. | |
| PH12013500500A1 (en) | Fused heteroaryls and their uses | |
| MX2012010127A (es) | Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos. | |
| MY161601A (en) | Films and compositions comprising the same | |
| IN2012DN03404A (enExample) | ||
| PH12013501311A1 (en) | Polymer systems | |
| IN2014DN02926A (enExample) | ||
| WO2011130697A3 (en) | Tissue targeting | |
| PH12012501548A1 (en) | Compositions comprising sugar-cysteine products | |
| MX344189B (es) | Formulaciones de mazindol. | |
| MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
| MX2013005699A (es) | Composiciones de interferon-beta estables conservadas. | |
| PH12012501547A1 (en) | Methods of preparing thiazolidines | |
| UA61166U (en) | Use of glucosamine hydrochloride as antiamnestic and antihypoxic agent | |
| UA41660U (en) | Use of jacton and mexidol as actoprotector | |
| UA52379U (ru) | Применение ЛИПИНА в качестве средства фригопротекторного действия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |